These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33158772)

  • 21. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.
    Hawkins N; Muszbek N; Evans R; Dequen-O'Byrne P; Jones T; McNamara L
    J Comp Eff Res; 2022 Aug; 11(11):805-813. PubMed ID: 35678206
    [No Abstract]   [Full Text] [Related]  

  • 22. Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.
    Ortiz Romero PL; Kim YH; Molloy K; Quaglino P; Scarisbrick J; Thornton S; Sandilands K; Dent JE; Nixon A; Williams A; Shinohara MM
    J Eur Acad Dermatol Venereol; 2024 Sep; ():. PubMed ID: 39315857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
    Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
    J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments.
    Herbosa CM; Semenov YR; Rosenberg AR; Mehta-Shah N; Musiek AC
    J Eur Acad Dermatol Venereol; 2020 May; 34(5):995-1003. PubMed ID: 31630443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.
    Johnson WT; Kartan S; Sokol K; Nikbakht N; Porcu P
    Leuk Lymphoma; 2021 Aug; 62(8):1877-1883. PubMed ID: 33618592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skindex-29 scores indicate poor quality of life in early stage mycosis fungoides.
    Shalabi D; Kartan S; O'Donnell M; Zaya R; Zhan T; Shi W; Alpdogan O; Porcu P; Nikbakht N
    J Dermatol Sci; 2020 May; 98(2):98-101. PubMed ID: 32362434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
    Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases.
    Oymanns M; Daum-Marzian M; Assaf C
    Curr Oncol; 2024 Sep; 31(9):5412-5421. PubMed ID: 39330028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
    Algarni AS; Ram-Wolff C; Bagot M; De Masson A
    Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
    Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
    Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphoma.
    Rolf D; Elsayad K; Eich HT
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1757-1761. PubMed ID: 33219856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.
    Teoli M; Mandel VD; Franceschini C; Saraceni PL; Cicini MP; Ardigò M
    Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):8118-8128. PubMed ID: 36394762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.
    Elsayad K; Kroeger K; Greve B; Moustakis C; Assaf C; Stadler R; Lenz G; Weishaupt C; Eich HT
    Strahlenther Onkol; 2020 Jan; 196(1):77-84. PubMed ID: 31591658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
    Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
    Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
    Ohuchi K; Fujimura T; Kambayashi Y; Amagai R; Lyu C; Tanita K; Sato Y; Aiba S
    Dermatol Ther; 2020 Jul; 33(4):e13487. PubMed ID: 32362053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
    Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
    Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life and psychological distress in patients with cutaneous lymphoma.
    Sampogna F; Frontani M; Baliva G; Lombardo GA; Alvetreti G; Di Pietro C; Tabolli S; Russo G; Abeni D
    Br J Dermatol; 2009 Apr; 160(4):815-22. PubMed ID: 19120325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
    Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
    Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
    Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
    J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.